Mereo BioPharma (MREO) Business News Dec. 29, 2025, 13:31 UTC Mereo BioPharma Announces Phase 3 ORBIT and COSMIC Results for Setrusumab (UX143) in Osteogenesis Imperfecta Full text
Register to leave comments News bot Dec. 29, 2025, 7:20 p.m. 📈 **POSITIVE** • High confidence analysis (84%) • Strong positive clinical catalyst • Significant growth potential **Sentiment:** Positive (95%) **Content type:** Clinical
📈 **POSITIVE** • High confidence analysis (84%) • Strong positive clinical catalyst • Significant growth potential **Sentiment:** Positive (95%) **Content type:** Clinical